NuCana (NCNA) Net Income towards Common Stockholders (2017 - 2025)

NuCana (NCNA) reported Net Income towards Common Stockholders of -$3.7 million for Q4 2025, down 339.46% on a YoY basis from $1.5 million in Q4 2024, and down 871.39% sequentially from -$379170.8 in Q3 2025.

NuCana (NCNA) Net Income towards Common Stockholders (2017 - 2025) Analysis & Trends

NuCana (NCNA) has 9 years of Net Income towards Common Stockholders data on file, last reported at -$3.7 million in Q4 2025.

  • For the quarter ending Q4 2025, Net Income towards Common Stockholders fell 339.46% year-over-year to -$3.7 million; the trailing twelve-month figure through Dec 2025 stood at -$39.3 million (down 62.57% YoY), and the FY2025 full-year result was -$41.8 million, down 72.06% from the prior year.
  • Net Income towards Common Stockholders slipped to -$3.7 million in Q4 2025, from -$379170.8 in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $12.7 million in Q2 2021 to a low of -$32.2 million in Q2 2025.
  • A 5-year average of -$7.9 million and a median of -$8.6 million in 2023 frame the typical range for Net Income towards Common Stockholders.
  • Peak annual rise in Net Income towards Common Stockholders reached 268.77% in 2021, while the deepest fall reached 364.75% in 2021.
  • Tracing NCNA's Net Income towards Common Stockholders over 5 years: stood at -$18.4 million in 2021, then rose by 3.07% to -$17.8 million in 2022, then surged by 46.71% to -$9.5 million in 2023, then jumped by 91.18% to -$838126.7 in 2024, then slumped by 339.46% to -$3.7 million in 2025.
  • Business Quant data shows NCNA's Net Income towards Common Stockholders at -$3.7 million in Q4 2025, -$379170.8 in Q3 2025, and -$32.2 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Oculis Holding AG 66,801.52 Bn 66,801.23 Bn - -625.73
2 Nanobiotix 1,908.00 Bn 1,907.94 Bn - -
3 Akari Therapeutics 959.56 Bn 959.56 Bn - -14.46 Mn
4 BeOne Medicines 472.27 Bn 467.47 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 122.18 Bn 114.93 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 70.08 Bn 61.32 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 62.34 Bn 62.34 Bn - -0.68
8 Argenx Se 55.86 Bn 50.68 Bn 1.41 Bn 472.00 Mn
9 Alnylam Pharmaceuticals 37.50 Bn 34.49 Bn 959.66 Mn 205.99 Mn
10 NuCana 15.22 Bn 15.19 Bn - -3.68 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -3.68 Mn
Sep 30, 2025 -379,170.76
Jun 30, 2025 -32.17 Mn
Mar 31, 2025 -3.11 Mn
Dec 31, 2024 -838,126.70
Sep 30, 2024 -5.86 Mn
Jun 30, 2024 -8.83 Mn
Mar 31, 2024 -8.67 Mn
Dec 31, 2023 -9.50 Mn
Sep 30, 2023 -8.48 Mn
Jun 30, 2023 -6.77 Mn
Mar 31, 2023 -9.56 Mn
Dec 31, 2022 -17.83 Mn
Sep 30, 2022 -5.34 Mn
Jun 30, 2022 4.90 Mn
Mar 31, 2022 -11.28 Mn
Dec 31, 2021 -18.39 Mn
Sep 30, 2021 -11.09 Mn
Jun 30, 2021 12.70 Mn
Mar 31, 2021 -13.46 Mn